• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Age-related decreases in relapses among adults with relapsing-onset multiple sclerosis.成人复发缓解型多发性硬化症中与年龄相关的复发减少。
Mult Scler. 2020 Oct;26(12):1510-1518. doi: 10.1177/1352458519866613. Epub 2019 Jul 29.
2
Comparative Efficacy of Relapsing Multiple Sclerosis Therapies: Model-Based Meta-Analyses for Confirmed Disability Accumulation and Annualized Relapse Rate.复发型多发性硬化症治疗方案的疗效比较:基于模型的荟萃分析评估确认残疾进展和年化复发率。
Mult Scler Relat Disord. 2022 Aug;64:103908. doi: 10.1016/j.msard.2022.103908. Epub 2022 May 23.
3
Contribution of relapse-associated worsening to overall disability accrual in patients with relapsing-onset multiple sclerosis: A mediation analysis.复发相关恶化对复发缓解型多发性硬化患者总体残疾进展的影响:中介分析。
Mult Scler Relat Disord. 2022 Mar;59:103555. doi: 10.1016/j.msard.2022.103555. Epub 2022 Jan 22.
4
Relapses add to permanent disability in relapsing multiple sclerosis patients.复发会增加复发型多发性硬化症患者的永久性残疾。
Mult Scler Relat Disord. 2021 Aug;53:103029. doi: 10.1016/j.msard.2021.103029. Epub 2021 May 17.
5
The natural history of multiple sclerosis: a geographically based study 10: relapses and long-term disability.多发性硬化症的自然病史:基于地理的研究 10:复发和长期残疾。
Brain. 2010 Jul;133(Pt 7):1914-29. doi: 10.1093/brain/awq118. Epub 2010 Jun 9.
6
Determinants of therapeutic lag in multiple sclerosis.多发性硬化症治疗延迟的决定因素。
Mult Scler. 2021 Oct;27(12):1838-1851. doi: 10.1177/1352458520981300. Epub 2021 Jan 11.
7
Progression is independent of relapse activity in early multiple sclerosis: a real-life cohort study.早期多发性硬化症中疾病进展与复发活动无关:一项真实世界队列研究。
Brain. 2022 Aug 27;145(8):2796-2805. doi: 10.1093/brain/awac111.
8
Effectiveness and safety of switching to teriflunomide in older patients with relapsing multiple sclerosis: A real-world retrospective multicenter analysis.老年复发型多发性硬化症患者换用特立氟胺的有效性和安全性:一项真实世界回顾性多中心分析。
Mult Scler Relat Disord. 2023 Feb;70:104472. doi: 10.1016/j.msard.2022.104472. Epub 2022 Dec 18.
9
Mitoxantrone in relapsing-remitting and rapidly progressive multiple sclerosis: Ten-year clinical outcomes post-treatment with mitoxantrone.米托蒽醌治疗复发缓解型和快速进展型多发性硬化症:米托蒽醌治疗后十年的临床结果
Mult Scler Relat Disord. 2020 Sep;44:102330. doi: 10.1016/j.msard.2020.102330. Epub 2020 Jun 23.
10
How patients with multiple sclerosis acquire disability.多发性硬化症患者如何致残。
Brain. 2022 Sep 14;145(9):3147-3161. doi: 10.1093/brain/awac016.

引用本文的文献

1
HHV-6 and EBV reactivation in relapsing remitting multiple sclerosis: Disability, progression, and inflammation links.复发缓解型多发性硬化症中HHV-6和EBV的再激活:残疾、疾病进展与炎症的关联
iScience. 2025 Jul 5;28(8):113048. doi: 10.1016/j.isci.2025.113048. eCollection 2025 Aug 15.
2
Disease-modifying therapy during pregnancy and postpartum relapse activity in women with multiple sclerosis undergoing assisted reproductive technology treatment: a nationwide cohort study.多发性硬化症女性在接受辅助生殖技术治疗期间的疾病修饰治疗及产后复发活动:一项全国性队列研究。
BMJ Neurol Open. 2025 Jul 3;7(2):e001092. doi: 10.1136/bmjno-2025-001092. eCollection 2025.
3
Peripheral HLA-DRCD141 Classical Monocytes Predict Relapse Risk and Worsening in Multiple Sclerosis.外周血 HLA-DR⁺CD14⁺ 经典单核细胞可预测多发性硬化症的复发风险及病情恶化。
Neurol Neuroimmunol Neuroinflamm. 2025 Sep;12(5):e200426. doi: 10.1212/NXI.0000000000200426. Epub 2025 Jul 3.
4
Outcomes in patients with multiple sclerosis and solid organ cancers treated with immune checkpoint inhibitors.接受免疫检查点抑制剂治疗的多发性硬化症和实体器官癌症患者的预后。
Neurooncol Adv. 2025 Mar 4;7(1):vdaf048. doi: 10.1093/noajnl/vdaf048. eCollection 2025 Jan-Dec.
5
Predictors of early disability accumulation in newly diagnosed multiple sclerosis: clinical, imaging and cerebrospinal fluid measures.新诊断多发性硬化症早期残疾累积的预测因素:临床、影像学和脑脊液指标
J Neurol Neurosurg Psychiatry. 2025 Feb 17. doi: 10.1136/jnnp-2024-335037.
6
Discontinuation of First-Line Disease-Modifying Therapy in Patients With Stable Multiple Sclerosis: The DOT-MS Randomized Clinical Trial.稳定型多发性硬化症患者一线疾病修正治疗的停药:DOT-MS随机临床试验
JAMA Neurol. 2025 Feb 1;82(2):123-131. doi: 10.1001/jamaneurol.2024.4164.
7
Aging is associated with reduced inflammatory disease activity independent of disease duration in relapsing multiple sclerosis trial populations.在复发型多发性硬化症临床试验人群中,与疾病持续时间无关,衰老与炎症性疾病活动减少相关。
Mult Scler. 2024 Sep;30(10):1296-1308. doi: 10.1177/13524585241272938. Epub 2024 Sep 8.
8
Correlates and trajectories of relapses in relapsing-remitting multiple sclerosis.复发缓解型多发性硬化症复发的相关性和轨迹。
Neurol Sci. 2024 May;45(5):2181-2189. doi: 10.1007/s10072-023-07155-3. Epub 2023 Nov 17.
9
Innate and adaptive immune abnormalities underlying autoimmune diseases: the genetic connections.自身免疫性疾病的先天和适应性免疫异常:遗传关联。
Sci China Life Sci. 2023 Jul;66(7):1482-1517. doi: 10.1007/s11427-021-2187-3. Epub 2023 Feb 3.
10
Molecular Mechanisms of Immunosenescene and Inflammaging: Relevance to the Immunopathogenesis and Treatment of Multiple Sclerosis.免疫衰老和炎症衰老的分子机制:与多发性硬化症的免疫发病机制及治疗的相关性
Front Neurol. 2022 Feb 25;12:811518. doi: 10.3389/fneur.2021.811518. eCollection 2021.

本文引用的文献

1
Changes in the Risk of Reaching Multiple Sclerosis Disability Milestones In Recent Decades: A Nationwide Population-Based Cohort Study in Sweden.近几十年来多发性硬化症达到残疾里程碑风险的变化:瑞典一项全国范围内基于人群的队列研究。
JAMA Neurol. 2019 Jun 1;76(6):665-671. doi: 10.1001/jamaneurol.2019.0330.
2
The prevalence of MS in the United States: A population-based estimate using health claims data.美国多发性硬化症的患病率:基于健康索赔数据的人群估计。
Neurology. 2019 Mar 5;92(10):e1029-e1040. doi: 10.1212/WNL.0000000000007035. Epub 2019 Feb 15.
3
Discontinuation of disease-modifying therapy in patients with multiple sclerosis over age 60.60 岁以上多发性硬化症患者中断疾病修正治疗。
Mult Scler. 2019 Apr;25(5):699-708. doi: 10.1177/1352458518765656. Epub 2018 Mar 20.
4
Unmet needs, burden of treatment, and patient engagement in multiple sclerosis: A combined perspective from the MS in the 21st Century Steering Group.多发性硬化症未满足的需求、治疗负担和患者参与:21 世纪多发性硬化症指导小组的综合观点。
Mult Scler Relat Disord. 2018 Jan;19:153-160. doi: 10.1016/j.msard.2017.11.013. Epub 2017 Nov 21.
5
Comparison of preferences of healthcare professionals and MS patients for attributes of disease-modifying drugs: A best-worst scaling.比较医疗保健专业人员和多发性硬化症患者对疾病修正药物属性的偏好:最佳最差标度法。
Health Expect. 2018 Feb;21(1):171-180. doi: 10.1111/hex.12599. Epub 2017 Jul 21.
6
Disease-modifying therapies can be safely discontinued in an individual with stable relapsing-remitting MS - Commentary.对于病情稳定的复发缓解型多发性硬化症患者,疾病修正治疗可以安全停用——评论
Mult Scler. 2017 Aug;23(9):1192-1193. doi: 10.1177/1352458517717809. Epub 2017 Jul 4.
7
Stopping Disease-Modifying Therapy in Nonrelapsing Multiple Sclerosis: Experience from a Clinical Practice.停止非复发性多发性硬化症的疾病修饰治疗:临床实践经验
Int J MS Care. 2017 Jan-Feb;19(1):11-14. doi: 10.7224/1537-2073.2015-032.
8
Cost-effectiveness of different strategies for treatment relapsing-remitting multiple sclerosis.复发缓解型多发性硬化症不同治疗策略的成本效益
J Comp Eff Res. 2017 Mar;6(2):97-108. doi: 10.2217/cer-2016-0056. Epub 2017 Jan 25.
9
Discontinuation of disease-modifying therapies in multiple sclerosis - Clinical outcome and prognostic factors.多发性硬化症中疾病修饰疗法的停用——临床结果和预后因素
Mult Scler. 2017 Aug;23(9):1241-1248. doi: 10.1177/1352458516675751. Epub 2016 Oct 20.
10
Can we stop immunomodulatory treatments in secondary progressive multiple sclerosis?我们能否停止继发进展型多发性硬化的免疫调节治疗?
Eur J Neurol. 2017 Feb;24(2):237-244. doi: 10.1111/ene.13181. Epub 2016 Oct 18.

成人复发缓解型多发性硬化症中与年龄相关的复发减少。

Age-related decreases in relapses among adults with relapsing-onset multiple sclerosis.

机构信息

Division of Health Policy & Management, School of Public Health, University of Minnesota, Minneapolis, MN, USA.

Division of Neurology, Faculty of Medicine, The University of British Columbia and Djavad Mowafaghian Centre for Brain Health, Vancouver, BC, Canada.

出版信息

Mult Scler. 2020 Oct;26(12):1510-1518. doi: 10.1177/1352458519866613. Epub 2019 Jul 29.

DOI:10.1177/1352458519866613
PMID:31354041
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6986982/
Abstract

BACKGROUND

Relapsing-onset multiple sclerosis (MS) typically starts in early- to mid-adulthood, yet the trajectory of disease activity over the subsequent lifetime remains poorly defined. Previous studies have not quantified the age-specific portion of decreases in annualized relapse rates (ARR).

OBJECTIVE

The aim of this article is to determine, under a range of disease-related assumptions, the age-specific component of decreases in ARR over time among adults with relapsing-onset MS.

METHODS

We used a simulation modeling approach to examine a range of assumptions about changes in ARR due to age versus disability status. Scenarios included variations in initial ARR and rate of worsening on the Expanded Disability Status Scale. Model parameters were developed through analysis of MS patients in British Columbia, Canada, and literature review.

RESULTS

We found a substantial age-specific decrease in ARR in all simulated scenarios, independent of disability worsening. Under a range of clinically plausible assumptions, 88%-97% of the decrease was attributed to age and 3%-13% to disability. The age-specific decrease ranged from 22% to 37% per 5 years for a wide range of initial ARR (0.33-1.0).

CONCLUSION

Decreases in ARR were due mostly to age rather than disability status. To facilitate informed decision making in MS, it is important to quantify the dynamic relationship between relapses and age.

摘要

背景

复发缓解型多发性硬化症(MS)通常在成年早期至中期发病,但随后一生中疾病活动的轨迹仍不清楚。以前的研究尚未量化年度复发率(ARR)下降的年龄特异性部分。

目的

本文旨在确定在一系列与疾病相关的假设下,复发缓解型 MS 成人中 ARR 随时间的年龄特异性下降部分。

方法

我们使用模拟建模方法来检查由于年龄与残疾状况而导致 ARR 变化的一系列假设。方案包括初始 ARR 和扩展残疾状况量表恶化率的变化。模型参数是通过对加拿大不列颠哥伦比亚省的 MS 患者进行分析和文献综述得出的。

结果

我们发现,在所有模拟场景中,ARR 都有明显的年龄特异性下降,与残疾恶化无关。在一系列临床合理的假设下,ARR 下降的 88%-97%归因于年龄,3%-13%归因于残疾。ARR 初始值为 0.33-1.0 时,ARR 的年龄特异性下降范围为每 5 年 22%-37%。

结论

ARR 的下降主要归因于年龄而不是残疾状况。为了促进 MS 中的知情决策,量化复发与年龄之间的动态关系非常重要。